Analysts predict that OncoSec Medical Inc (NASDAQ:ONCS) will report earnings per share of ($1.37) for the current quarter, Zacks reports. Zero analysts have made estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings of ($1.80) per share in the same quarter last year, which would suggest a positive year over year growth rate of 23.9%. The business is expected to issue its next quarterly earnings results on Wednesday, July 24th.
On average, analysts expect that OncoSec Medical will report full year earnings of ($5.27) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will post earnings of ($4.20) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for OncoSec Medical.
Several research firms have commented on ONCS. Maxim Group reiterated a “buy” rating and set a $9.00 price objective on shares of Pareteum in a research report on Friday, June 28th. Zacks Investment Research lowered shares of Hanger from a “hold” rating to a “sell” rating in a research report on Tuesday, May 28th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. OncoSec Medical has an average rating of “Buy” and a consensus target price of $20.75.
In other news, Director Alpha Holdings, Inc. purchased 90,000 shares of the stock in a transaction dated Tuesday, July 16th. The shares were acquired at an average cost of $2.30 per share, for a total transaction of $207,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 5.40% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp boosted its stake in OncoSec Medical by 484.1% in the 4th quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 83,150 shares in the last quarter. Northern Trust Corp boosted its stake in OncoSec Medical by 33.6% in the 4th quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 28,914 shares in the last quarter. Geode Capital Management LLC boosted its stake in OncoSec Medical by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 163,405 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in OncoSec Medical by 98.2% in the 4th quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 240,843 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.